Last quarter (Q ), Regen Biopharma's total revenue was $31.64K, a decrease of -46.43% from the same quarter last year. In Q, Regen Biopharma's net income was $-122.47K. See Regen Biopharma’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Sep 22	Sep 21	Sep 20	Sep 19	Sep 18
Total Revenue	$ 126.56K	$ 125.52K	$ 61.19K	$ 110.00K	$ 110.00K	$ 100.00K
Cost of Revenue	-	$ 117.25K	-	-	-	-
Gross Profit	$ 126.56K	$ 8.27K	$ 61.19K	-	-	-
Operating Expense	$ 266.02K	$ 347.87K	$ 261.96K	$ 319.32K	$ 866.78K	$ 1.53M
Operating Income	$ -112.04K	$ -339.61K	$ -200.77K	$ -209.32K	$ -756.78K	$ -1.43M
Net Non Operating Interest Income Expense	$ -60.98K	$ -138.26K	$ -315.78K	$ -942.93K	$ -1.70M	$ -1.55M
Other Income Expense	$ 209.21K	$ -3.28M	$ 5.40M	$ 4.57M	$ -165.44K	$ -1.74M
Pretax Income	$ -413.99K	$ 2.74M	$ -6.77M	$ 3.41M	$ -2.62M	$ -4.72M
Tax Provision	-	$ 300.00K	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -386.56K	$ 2.44M	$ -6.77M	$ 2.73M	$ -2.62M	$ -4.72M
Basic EPS	$ -0.10	-	-	$ <0.01	$ >-0.01	$ -0.03
Diluted EPS	$ -0.10	-	-	$ <0.01	$ >-0.01	$ -0.03
Basic Average Shares	$ 12.57M	$ 4.70B	$ 2.01M	$ 1.41B	$ 2.07B	$ 152.09M
Diluted Average Shares	$ 12.57M	$ 4.70B	$ 2.01M	$ 1.41B	$ 2.07B	$ 152.09M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	$ 18.55K	$ 60.00K	$ 60.00K
Total Expenses	$ 266.02K	$ 465.12K	$ 261.96K	$ 319.32K	$ 866.78K	$ 1.53M
Net Income From Continuing And Discontinued Operation	$ -626.43K	$ 2.44M	$ -6.77M	$ 2.73M	$ -2.62M	$ -4.72M
Normalized Income	$ -568.70K	-	-	$ -602.13K	$ -2.46M	$ -3.25M
Interest Expense	-	-	-	$ 942.93K	$ 1.70M	$ 1.56M
EBIT	$ -353.01K	$ 2.88M	$ -6.45M	$ 4.36M	$ -920.92K	$ -3.15M
EBITDA	$ -259.15K	$ 2.95M	$ -6.45M	$ 4.36M	$ -920.92K	$ -3.15M

Currency in USD

Regen Biopharma Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing